P47.10 Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung
W. Wang(The Ohio State University), David P. Carbone(Vanderbilt University), Konstantin Shilo(The Ohio State University Wexner Medical Center), Håkan Mellstedt(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), C M Croce(The Ohio State University), Johan Schultz(Kancera (Sweden)), Joseph M. Amann(The Ohio State University), Alyssa Shulman(The Ohio State University)
Cited by 0
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k